rss
J Neurol Neurosurg Psychiatry 74:294-298 doi:10.1136/jnnp.74.3.294
  • Paper

[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease

  1. A Winogrodzka1,
  2. P Bergmans1,
  3. J Booij2,
  4. E A van Royen2,
  5. J C Stoof1,
  6. E C Wolters1
  1. 1Department of Neurology, Vrije Universiteit Medical Centre; Graduate School for Neurosciences, Amsterdam, Netherlands
  2. 2Department of Nuclear Medicine, Academic Medical Centre, University of Amsterdam
  1. Correspondence to:
 Dr A Winogrodzka, Vrije Universiteit Medisch Centrum, Department of Neurology, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands;
 a.winogrodzka{at}vumc.nl
  • Received 22 April 2002
  • Accepted 23 October 2002
  • Revised 21 August 2002

Abstract

Objectives:To examine the validity of [123I]β-CIT SPECT for monitoring the progression of dopaminergic degeneration in Parkinson’s disease; to investigate the influence of short term treatment with D2receptor agonists on striatal [123I]β-CIT binding; and to determine the sample size and frequency of SPECT imaging required to demonstrate a significant effect of a putative neuroprotective agent.

Methods:A group of 50 early stage Parkinson’s disease patients was examined. Two SPECT imaging series were obtained, 12 months apart. The mean annual change in the ratio of specific to non-specific [123I]β-CIT binding to the striatum, putamen, and caudate nucleus was used as the outcome measure.

Results:A decrease in [123I]β-CIT binding ratios between the two images was found in all regions of interest. The average decrease in [123I]β-CIT binding ratios was about 8% in the whole striatum, 8% in the putaminal region, and 4% in the caudate region. Comparison of scans done in nine patients under two different conditions—in the off state and while on drug treatment—showed no significant alterations in the expression of striatal dopamine transporters as measured using [123I]β-CIT SPECT. Power analysis indicated that to detect a significant (p < 0.05) effect of a neuroprotective agent with 0.80 power and 30% of predicted protection within two years, 216 patients are required in each group when the effects are measured in the whole putamen.

Conclusions:[123I]β-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in Parkinson’s disease and may provide an objective method of measuring the effectiveness of neuroprotective treatments. Short term treatment with a D2agonist does not have a significant influence on [123I]β-CIT binding to dopamine transporters. If the latter finding is replicated in larger groups of patients, it supports the suitability of [123I]β-CIT SPECT for examining the progression of neurodegeneration in patients being treated with D2receptor agonists.

Footnotes

  • Competing interests: none declared

  • See editorial commentary, pages 287.

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article